Search

Steven Feinmark Phones & Addresses

  • 220 Garfield St, Haworth, NJ 07641 (201) 385-3685
  • River Edge, NJ
  • 8601 Manchester Rd, Silver Spring, MD 20901
  • Chicago, IL

Work

Position: Professional/Technical

Education

Degree: Associate degree or higher

Publications

Us Patents

Two Pore Channels As Regulators Of Proliferation In Cancer

View page
US Patent:
8309528, Nov 13, 2012
Filed:
May 9, 2007
Appl. No.:
12/299852
Inventors:
Steven J. Feinmark - Haworth NJ, US
Richard B. Robinson - Cresskill NJ, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 48/00
C07H 21/02
C07H 21/04
US Classification:
514 44R, 536 231, 536 235
Abstract:
The present invention relates to the discovery that two pore K+ channel (2PK) gene expression is increased in tumors and tumor cell lines, especially prostate tumor cells. The present invention encompasses methods for disease diagnosis, drug screening and the treatment of cancer.

Method Of Treating A Condition Associated With Phosphorylation Of Task-1

View page
US Patent:
20070082374, Apr 12, 2007
Filed:
Jul 27, 2006
Appl. No.:
11/495012
Inventors:
Steven Feinmark - Haworth NJ, US
Richard Robinson - Cresskill NJ, US
International Classification:
A61K 31/41
A61K 31/277
A61K 31/202
C12Q 1/42
A61K 31/195
US Classification:
435021000, 514381000, 514531000, 514560000, 514563000
Abstract:
This invention provides methods and compositions for treating a condition associated with phosphorylation of TASK-1 in a subject comprising administering to the subject an amount of an agent effective to overcome the phosphorylation dependent loss of TASK-1 function so as to thereby treat the condition. In a specific embodiment of the invention the agent is a TREK-1 agonist.

Method Of Treating A Condition Associated With Phosphorylation Of Task-1

View page
US Patent:
20070259051, Nov 8, 2007
Filed:
Aug 2, 2006
Appl. No.:
11/498343
Inventors:
Steven J. Feinmark - Haworth NJ, US
Richard B. Robinson - Cresskill NJ, US
International Classification:
A61K 33/34
A61K 33/00
A61K 31/7076
A61K 31/277
A61K 31/195
US Classification:
424600, 514521, 514563, 514183, 514543, 424638, 514 47, 514651
Abstract:
This invention provides methods and compositions for treating a condition associated with phosphorylation of TASK-1 in a subject comprising administering to the subject an amount of an agent effective to overcome the phosphorylation dependent loss of TASK-1 function so as to thereby treat the condition. In a specific embodiment of the invention the agent is a TREK-1 agonist.

Two Pore Channels As A Therapeutic Target To Protect Against Myocardial Ischemia And As An Adjuvant In Cardiac Surgery

View page
US Patent:
20100048650, Feb 25, 2010
Filed:
Apr 4, 2007
Appl. No.:
12/296017
Inventors:
Ira S. Cohen - Stony Brook NY, US
Zhongju Lu - Port Jefferson Station NY, US
Irvin Krukenkamp - South Berwick ME, US
Peter R. Brink - Setauket NY, US
Richard B. Robinson - Cresskill NJ, US
Steven J. Feinmark - Haworth NJ, US
International Classification:
A61K 31/426
A61K 31/23
A61K 31/40
A61K 31/216
C12N 5/00
G01N 33/53
C12Q 1/02
A61P 9/00
US Classification:
514367, 514552, 514425, 514532, 435375, 436501, 435 29
Abstract:
The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel.

Two-Pore Channels As Regulators Of Proliferation In Cancer

View page
US Patent:
20130040298, Feb 14, 2013
Filed:
Oct 7, 2012
Appl. No.:
13/646718
Inventors:
Steven J. Feinmark - Haworth NJ, US
Richard B. Robinson - Cresskill NJ, US
Assignee:
The Trustees of Columbia University in the City of New York - New York City NY
International Classification:
C12Q 1/68
C12Q 1/04
G01N 33/574
G01N 33/566
US Classification:
435 611, 435 613, 435 721, 435 34, 435 723, 435 612
Abstract:
The present invention relates to the discovery that two pore Kchannel (2PK) gene expression is increased in tumors and tumor cell lines, especially prostate tumor cells. The present invention encompasses methods for disease diagnosis, drug screening and the treatment of cancer.

Two Pore Channels As A Therapeutic Target To Protect Against Myocardial Ischemia And As An Adjuvant In Cardiac Surgery

View page
US Patent:
20140113314, Apr 24, 2014
Filed:
Nov 29, 2012
Appl. No.:
13/689722
Inventors:
Ira S. Cohen - Stony Brook NY, US
Zhongju Lu - East Setenket NY, US
Richard B. Robinson - Cresskill NJ, US
Irvin B. Krukenkamp - South Berwick ME, US
Peter R. Brink - Setauket NY, US
Steven J. Feinmark - Haworth NJ, US
Assignee:
The Research Foundation of State University of New York - Albany NY
The Trustees of Columbia University in the City of New York - New York City NY
International Classification:
G01N 33/566
US Classification:
435 721
Abstract:
The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“KP channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarction or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel.
Steven J Feinmark from Haworth, NJ, age ~72 Get Report